The effects of heme alone and heme administered together with 3'-azido-3'-deoxythymidine (AZT) on human immuodeficiency virus replication in human peripheral blood lymphocytes and in the H9 cell line were studied. Heme enhanced the antiviral action of AZT against both drug-resistant and drug-sensitive viral strains; the heme effect was more pronounced against the latter. Moreover, heme alone displayed a significant ability to inhibit viral replication in concentrations markedly smaller than those required to inhibit the reverse transcriptase of Rauscher murine leukemia virus. The results of this study extend the range of pharmacological actions that metalloporphyrins exert in biological systems and suggest that further study of the interactions of the natural compound heme and human immunodeficiency virus chemotherapeutic agents such as AZT may be useful.
Antiviral therapy for the treatment of the acquired immunodeficiency syndrome (AIDS) is based on the assumption that continued retroviral replication is involved in both the pathogenesis and progression of the disease. Therefore, reverse transcriptase (RT) has been a major target for antiviral treatment in AIDS, and indeed most of the agents now being investigated, including zidovudine [3'-azido-3'-deoxythymidine (AZT)], which is currently in clinical use, act on this enzyme. The phosphorylated forms of these compounds inhibit human immunodeficiency virus (HIV) replication, in part, by acting as chain terminators (1, 2) . The RT of HIV is much more susceptible to the inhibitory effects of these phosphorylated dideoxynucleosides than are mammalian DNA polymerases. Administration of AZT has been shown to result in immunologic improvement and confers a survival advantage in HIV-infected patients with advanced immunodeficiency (3).
Among the major adverse effects of AZT administration in AIDS patients are anemia and neutropenia (4-7). AZT suppresses the proliferation of erythroid, granulocyte, macrophage, and primitive hematopoietic stem cells in a doserelated and time-dependent fashion (8) . In addition, longterm treatment with AZT may create a selective pressure, which affords a replication advantage to viruses of the drug-resistant phenotype. Such variants may be isolated from patients suffering from advanced HIV-associated disease, sometimes as early as 6 months after initiation of treatment (9) . Tsutsui and Mueller (10) reported that the virionassociated RT activity of Rauscher murine leukemia virus was inhibited by hemin § at a concentration of 100 ,uM. The inhibition of RT by this large concentration of hemin was reversible and appeared to be directed against the enzyme rather than the template. On the other hand, hemin did not inhibit the activity of RT purified from avian myeloblastosis virus.
Heme has long been known to play an important role in cellular differentiation and maturation processes (11) (12) (13) (14) . Conversely, many agents that either inhibit the synthesis or enhance the degradation of heme are known to have deleterious effects on cell function and viability, especially in the hemopoietic system (15, 16) . In view of the toxic actions of AZT on bone marrow stem cells, we recently examined the possibility that heme could exert a protective effect against the bone marrow toxicity of this chemotherapeutic agent. The results of that investigation showed that AZT-induced inhibition of colonyforming unit-erythroid, burst-forming unit-erythroid, and colony-forming unit-granulocyte/macrophage in both murine and human marrow could be counteracted in vitro to a considerable degree by concurrently administered heme (16) .
In this study, we examined the possible interactions of AZT and heme on HIV replication to determine whether heme could enhance the antiviral activity of AZT or might alone inhibit viral replication. Our The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 10 ,M) twice within 7 days. An aliquot of 0.5 ml was collected, an equal volume of FBS was added at day 7, and the sample was frozen at -70'C until assayed. For the HTLVIIIB AZTsensitive HIV, the 509%o inhibition concentration (IC50) of AZT was 0.008 ,uM (Fig. 1) . Heme alone at a concentration of 10 A.M almost completely blocked replication (Fig. 1) . The addition of heme with AZT reduced the IC50 of the drug markedly (Fig. 1) ; because ofthe efficacy ofheme alone at the 10 ,M dose, augmentation of the inhibitory effect of AZT could not be determined.
In the AZT-resistant HIV strain from patient 2, the IC50 Of AZT alone in the H9 cells exceeded 1 ,uM. Heme alone at 1 ,M had no effect on virus replication; at a concentration of 10 ,uM, substantial inhibition (-40%) observed (Fig. 2) . The differing effect of heme alone on the AZT-resistant strain in H9 cells as compared with PBLs (Table 1 ) may reflect inherent differences in these cell types.
The dose-response effect of heme alone on the replication of HIV in H9 cells of both the AZT-resistant and the AZT-sensitive strains of HIV was also examined. Viral replication of the drug-sensitive strain was reduced by 50% at a heme concentration <0.05 iLM (Fig. 3) ; for the drugresistant strain the comparable inhibitory concentration of heme was ==15 jiM (Fig. 4) .
These data indicate that heme (10 juM) alone was able to inhibit replication of an AZT-sensitive isolate in cultured PBLs and that in combination with AZT heme in concentrations of 1 juM or 10 jLM greatly enhanced AZT efficacy against a drug-resistant HIV strain in such cultures. Against both AZT-sensitive and AZT-resistant viral strains grown in H9 cells, heme alone displayed inhibitory properties and also augmented the antiviral actions of AZT against the AZTsensitive viral isolates. The doses of heme required for these actions were markedly smaller than the dose of heme required to inhibit virus-associated RT activity of Rauscher murine leukemia virus (10) and are significantly lower than the concentrations of heme used experimentally in mamma- hian cell systems where they have proved to be noncytotoxic (7, 28 (29, 30) . It is of interest in this respect that while neither heme nor AZT alone exerted an inhibitory effect on the AZTresistant HIV (patient 2, Table 1 ) the compounds, when administered together, profoundly inhibited virus replication. This finding raises the possibility that the viral mutation leading to AZT resistance affects the site or the manner in which heme may interact with the virus.
It should be noted that aberrations of heme metabolism, manifest as a porphyric clinical syndrome, have been identified by Wissel et al. (31) and other groups (32, 33) in some AIDS patients. Further, erythropoietin has been shown to have a beneficial effect on the anemia associated with this disorder (34, 35) . Erythropoietin, in vitro, increases the activity of the rate-limiting enzyme in heme synthesis, 8-aminolevulinate synthase (36, 37) , and elevates cellular heme content. Thus, it may be of potential clinical importance to examine further the integrity of heme synthetic and degradative processes in AIDS patients and to determine if the actions of heme described in this report extend to other heme-like molecules and other HIV isolates. G 
